Prozone effect of serum IgE levels in a case of plasma cell leukemia

Journal of Hematology and Oncology

Volumn 3, Issue , 2010, Pages

  Talamo, Giampaolo ^a   Castellani, William ^a   Dolloff, Nathan G ^a  

^a PENN STATE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENCE JONES PROTEIN; BORTEZOMIB; CD20 ANTIGEN; CD38 ANTIGEN; CD56 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IMMUNOGLOBULIN E; LENALIDOMIDE; SYNDECAN 1; THALIDOMIDE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BACKACHE; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CAPILLARY ZONE ELECTROPHORESIS; CASE REPORT; CAUCASIAN; COMPLEX FORMATION; CYTOGENETICS; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LEUKEMIA REMISSION; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA CELL LEUKEMIA; PROTEINURIA; BLOOD; IMMUNOLOGY; LABORATORY DIAGNOSIS; MIDDLE AGED;

FALSE NEGATIVE REACTIONS; HUMANS; IMMUNOGLOBULIN E; LEUKEMIA, PLASMA CELL; MALE; MIDDLE AGED; MULTIPLE MYELOMA;

EID: 77956490377     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-3-32     Document Type: Article

References (20)

1. IgE lambda monoclonal gammopathy and amyloidosis. JM Jako T Gesztesi I Kaszas, Int Arch Allergy Immunol 1997 112 415 421 10.1159/000237490 9104800
2. Immunological studies of an atypical (myeloma) immunoglobulin. SG Johansson H Bennich, Immunology 1967 13 381 394 4168094
3. Low IgE monoclonal gammopathy level in serum highlights 20-yr survival in a case of IgE multiple myeloma. MJ Hayes JL Carey JC Krauss DL Hedstrom RL Gulbranson DF Keren, Eur J Haematol 2007 78 353 357 10.1111/j.1600-0609.2007. 00825.x 17378894
4. IgE-type multiple myeloma with the late development of IgA2 kappa and plasma cell leukaemia. W Chiu H Pullon ST Woon P Oei R The R Ameratunga, Pathology 42 82 84 10.3109/00313020903434660 20025486
5. Skin involvement in immunoglobulin E multiple myeloma. JL Wozney F Ahmed MG Bayerl WC Ehmann G Talamo, J Clin Oncol 2009 27 637 638 10.1200/JCO.2008.20. 1491 19064952
6. IgE myeloma: a case presentation and a review of the literature. KJ Kairemo M Lindberg M Prytz, Scand J Clin Lab Invest 1999 59 451 456 10.1080/00365519950185472 10612556
7. IgE immunoglobulin. Br Med J 1972 4 250 251 10.1136/bmj.4.5835.250 5083879
8. A new case of IgE myeloma. F Invernizzi G Monti AG Caviglia P Meroni C Zanussi, Acta Haematol 1991 85 41 44 10.1159/000204851 2011930
9. A new case of IgE myeloma. RL Alexander Jr ST Roodman PJ Petruska CC Tsai CG Janney, Clin Chem 1992 38 2328 2332 1424132
10. IgE myelomatosis. Presentation of a new case and summary of literature. S Hegewisch K Mainzer D Braumann, Blut 1987 55 55 60 10.1007/BF00319644 3607296
11. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. B Barlogie E Anaissie F van Rhee J Haessler K Hollmig M Pineda-Roman M Cottler-Fox A Mohiuddin Y Alsayed G Tricot, et al. Br J Haematol 2007 138 176 185 10.1111/j.1365-2141.2007.06639.x 17593024
12. IgE plasma cell leukemia successfully treated with combination VAD (vincristine, doxorubicin, dexamethasone) and MP (melphalan, prednisolone) followed by interferon-alpha. N Yamagata C Shimazaki H Goto T Hirata E Ashihara N Oku T Inaba N Fujita M Nakagawa, Am J Hematol 1994 45 262 264 10.1002/ajh.2830450315 8296801
13. Plasma cell leukemia producing monoclonal immunoglobulin E. Y Takemura M Ikeda K Kobayashi Y Nakazawa Y Mori T Mitsuishi H Ishigame F Kameko K Fujita R Ichinohasama, Int J Hematol 2009 90 402 406 10.1007/s12185-009-0407-1 19728026
14. Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis. VH Jimenez-Zepeda VJ Dominguez-Martinez, Int J Hematol 2009 89 259 268 10.1007/s12185-009-0288-3 19326058
15. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. H Avet-Loiseau R Garand L Lode JL Harousseau R Bataille, Blood 2003 101 1570 1571 10.1182/blood-2002-08-2436 12393502
16. IgE myeloma with elevated level of serum CA125. ML Wang Q Huang TX Yang, J Zhejiang Univ Sci B 2009 10 559 562 10.1631/jzus.B0820399 19585675
17. Long-term follow-up study on the role of serum CA-125 as a prognostic factor in 221 newly diagnosed patients with Hodgkin's lymphoma. F Russo S Lastoria G Svanera G Capobianco A de Chiara R Francia E Squame F de Martinis A Pinto, Leuk Lymphoma 2007 48 723 730 10.1080/10428190601183710 17454630
18. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. A Dispenzieri R Kyle G Merlini JS Miguel H Ludwig R Hajek A Palumbo S Jagannath J Blade S Lonial, et al. Leukemia 2009 23 215 224 10.1038/leu.2008.307 19020545
19. Dilution protocols for detection of hook effects/prozone phenomenon. AW Butch, Clin Chem 2000 46 1719 1721 11017960
20. Costa FP, Dourado DA, Borsoi CS, Deeke CD, Valvasori M, Colella R: Transfusion medicine illustrated. Hyperviscosity and the prozone effect in multiple myeloma. Transfusion 2008, 48:2056.